Fluicell AB (publ) ("Fluicell" or the "Company") hereby announces that the Company is part of a collaboration that has received funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, for the development of tissue-based implants for type 1 diabetes treatment. The funded project is a collaboration between Fluicell and a prominent diabetes researcher at a top ranked American medical university and combines [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.